Ultrasonic Electrosurgical Devices Market By Product Type (Ultrasonic Scalpel Systems, Handpieces, Generators); By Application (Minimally Invasive Surgery, Oncology, Gastrointestinal Surgery); By End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ultrasonic Electrosurgical Devices Market: Procedure Growth, Hybrid Energy Systems, and Recurring Surgical Demand Shape Competition

The Global Ultrasonic Electrosurgical Devices Market was valued at USD 4.07 billion in 2025 and is projected to reach approximately USD 7.15 billion by 2032, growing at a CAGR of 8.4%, according to Strategic Market Research.

 

Ultrasonic and hybrid electrosurgical devices are regulated by the FDA mainly under product codes LFL (ultrasonic surgical instruments) and GEI (electrosurgical cutting and coagulation systems). Within this framework, key FDA-cleared platforms include Ethicon’s Harmonic system (Johnson & Johnson), Olympus’s Thunderbeat and Sonicbeat systems, and ultrasonic devices from Mindray, which together represent the core of widely used clinical technologies. Innovation is increasingly focused on next-generation systems incorporating artificial intelligence, smart energy modulation, and improved tissue recognition to enhance surgical precision and safety.

 

Among approved systems, Ethicon’s Harmonic platform is one of the most widely adopted, using ~55 kHz ultrasonic vibration to cut tissue and seal vessels up to 5 mm in diameter. Olympus’s Thunderbeat and USG-410 systems combine ultrasonic and advanced bipolar energy to enable simultaneous cutting and vessel sealing, improving procedural efficiency. Mindray’s ultrasonic systems include Smart Tissue Sensing, which adjusts power delivery based on tissue response, and Enhanced Vessel Sealing technology to improve hemostatic control.

 

Pipeline innovation is centered on smart energy systems that provide real-time feedback on tissue properties to reduce thermal spread and collateral damage. A key trend is miniaturization, with smaller, more ergonomic instruments designed for laparoscopic, minimally invasive, and robotic-assisted surgery. Additionally, multimodal energy platforms are emerging that integrate ultrasonic, bipolar, and radiofrequency energy into a single system to improve versatility, reduce equipment footprint, and streamline operating room workflows.

 

High-Volume Surgery Forms the Core Demand Base

Demand comes from operations requiring controlled tissue division, vessel sealing, coagulation, or hemostasis. General surgery provides the broadest pool through cholecystectomy, colorectal resection, bariatric surgery, hernia repair, and liver procedures. Gynecology adds hysterectomy, myomectomy, oophorectomy, and cancer surgery, while thyroid, urologic, thoracic, and selected pediatric procedures expand the addressable market.

AHRQ’s 2014 U.S. estimates included about 950,000 cholecystectomies and common-duct exploration procedures, 513,600 hysterectomies, 310,000 colorectal resections, 282,200 oophorectomies, and 131,300 thyroidectomies. These procedure pools support recurring demand, although instrument selection varies by surgeon, procedure complexity, vessel size, hospital contract, and the availability of bipolar sealers, monopolar instruments, staplers, clips, sutures, ligatures, and cold instruments.

The movement of suitable procedures into outpatient settings adds another growth factor. Hospital outpatient departments and ambulatory surgical centers emphasize procedure-level cost, compact equipment, standardized instrument sets, predictable room turnover, and supply availability. Suppliers supporting several specialties through one generator platform can improve their position in these settings.

 

Bariatric Surgery Creates Demand but Faces Procedure-Volume Pressure

Bariatric and metabolic surgery is an important application because sleeve gastrectomy, gastric bypass, and revision procedures require extensive tissue division and vessel management. The American Society for Metabolic and Bariatric Surgery estimated 270,089 U.S. procedures in 2023, including 157,254 sleeve gastrectomies, 63,132 Roux-en-Y gastric bypasses, and 32,267 revisions.

More than 22 million U.S. adults were estimated to have severe obesity, while WHO reported more than 890 million adults living with obesity worldwide in 2022. Only a small share proceeds to surgery because access depends on clinical eligibility, insurance coverage, referral patterns, treatment preference, and medical alternatives.

Manufacturers must track the mix of sleeve gastrectomy, gastric bypass, revisions, and endoscopic procedures rather than relying only on obesity prevalence. Complex operations may require different instrument configurations and consumption patterns than sleeve gastrectomy or nonsurgical interventions.

 

Disease Burden Supports a Diversified Surgical Pool

The United States recorded 155,662 new colorectal cancer cases in 2023, while combined IARC estimates for colon and rectal cancer reached about 1.98 million new cases globally in 2024. Surgery is central for many localized and selected advanced cases, but ultrasonic instruments compete with staplers, bipolar devices, monopolar tools, clips, and conventional dissection methods.

An AHRQ evidence review estimated that 26 million U.S. women aged 15–50 had uterine fibroids, including more than 15 million with symptoms or health concerns. A GBD-based analysis estimated 226.05 million prevalent cases globally in 2019. Direct device demand is concentrated among patients undergoing hysterectomy or myomectomy.

Thyroid surgery includes benign nodules, goiter, hyperthyroidism, and thyroid cancer. NCI estimated that more than 1.03 million people were living with thyroid cancer in the United States in 2023, while IARC estimated 959,281 new cases globally in 2024. Ultrasonic instruments are used in selected thyroidectomy and neck-dissection procedures.

Liver surgery is smaller but more complex. IARC estimated 843,045 new liver and intrahepatic bile-duct cancer cases globally in 2024. Demand is concentrated in specialist centers because tumor stage, liver function, anatomy, and overall health determine eligibility for resection.

 

Disposable Instruments Drive Revenue and Hospital Contracting

Ultrasonic scalpel systems, including shears, scalpels, and dissectors, generate the largest recurring revenue stream because many are consumed during individual operations. Generators, handpieces, batteries, chargers, and trays create lower-frequency installation and replacement demand. Manufacturers may place or discount capital equipment to secure ongoing purchases of compatible instruments.

Hospital switching costs extend beyond the price of one device. Surgeons and operating-room teams must become familiar with the platform, while procurement teams evaluate compatibility, service coverage, procedure range, inventory, sterilization needs, contract terms, and supply reliability. A broad portfolio can therefore be commercially stronger than a single instrument with isolated technical advantages.

 

Reimbursement and Cost per Procedure Influence Adoption

Ultrasonic instruments are generally paid for within the economics of the full surgical episode rather than through a separate product-specific reimbursement pathway. Hospitals assess whether a premium-priced instrument lowers total procedure cost, reduces device exchanges, supports faster workflow, or allows one platform to serve multiple specialties.

Centralized procurement and health-system consolidation strengthen this pressure. Large systems negotiate bundled agreements across surgical-energy categories, making portfolio breadth, service support, rebates, product availability, and contract pricing important competitive tools.

 

Hybrid Energy, Cordless Design, and Platform Breadth Shape Competition

Johnson & Johnson’s HARMONIC portfolio benefits from broad specialty coverage and an established base of compatible generators and disposable instruments. Medtronic’s Sonicision system competes through cordless operation and reusable power components. Olympus focuses on hybrid energy through THUNDERBEAT, which combines ultrasonic cutting with bipolar vessel sealing. BOWA participates through LOTUS and ARC LOTUS systems for open and laparoscopic procedures.

Hospitals increasingly favor platforms that can serve several specialties, reduce equipment variation, and simplify inventory. Hybrid and cordless designs shift competition toward workflow, instrument consolidation, and operating-room mobility rather than cutting performance alone.

 

Regulatory Entry, Reprocessing, and Product Safety Alter Market Dynamics

Representative products enter the U.S. market through the FDA 510(k) pathway under the Class II category for ultrasonic surgical instruments. The pathway has enabled established manufacturers and newer Asian suppliers to introduce systems through predicate-device comparisons.

Reprocessing challenges the single-use pricing model in the United States. FDA-cleared reprocessed ultrasonic instruments give hospitals another way to reduce supply costs while continuing to use familiar platforms. Original manufacturers may respond through contracting, redesign, service packages, new-generation devices, or pricing incentives.

Product safety also affects procurement. Recalls or adverse-event concerns can delay hospital conversions, trigger contract reviews, increase inventory controls, and create openings for competitors. Commercial recovery depends on corrective actions, replacement availability, regulatory closure, and surgeon confidence.

 

Ultrasonic Electrosurgical Devices Market Segmentation

The following segment estimates are calculated against the USD 4.07 billion global market in 2025 and USD 7.15 billion forecast for 2032. Strategic Market Research derived the shares and growth rates from procedure mix, recurring instrument demand, replacement cycles, care-setting shifts, regional adoption, and competitive activity.

By Product Type

Ultrasonic scalpel systems represented the largest product category with an estimated 58.0% market share in 2025, equal to USD 2.361 billion. The segment is projected to reach USD 4.280 billion by 2032 at a CAGR of 8.9%. Its leadership reflects recurring demand for shears, scalpels, and dissectors used directly during surgery. Disposable or single-patient-use instruments create revenue each time an adopting procedure is performed.

Handpieces accounted for an estimated 26.0% share and USD 1.058 billion in 2025. The segment is forecast to reach USD 1.840 billion by 2032, growing at a CAGR of 8.2%. Demand is supported by expansion of compatible platforms, replacement needs, procedure-specific configurations, and ergonomic or cordless designs.

Generators held an estimated 16.0% share in 2025, representing USD 651 million. Revenue is projected to reach USD 1.030 billion by 2032 at a CAGR of 6.8%. Growth is slower because generators are reusable and support many procedures before replacement. Sales arise from new installations, platform upgrades, hospital expansion, equipment replacement, and conversions from competing systems.

 

By Application

Minimally invasive surgery was the largest application segment, accounting for an estimated 50.0% of the market and USD 2.035 billion in 2025. It is projected to reach USD 3.770 billion by 2032 at a CAGR of 9.2%, making it the fastest-growing application. Cholecystectomy, hysterectomy, bariatric surgery, colorectal resection, hernia repair, and selected urologic and thoracic operations support demand for instruments that can cut, dissect, coagulate, and seal through limited-access approaches.

Oncology represented an estimated 28.0% share and USD 1.140 billion in 2025. The segment is forecast to reach USD 2.000 billion by 2032 at a CAGR of 8.4%. Demand comes from selected colorectal, thyroid, liver, gynecologic, thoracic, and urologic cancer surgeries. Growth depends on resection eligibility, procedure complexity, and advanced-energy adoption in specialist centers.

Gastrointestinal surgery accounted for an estimated 22.0% share and USD 895 million in 2025. Revenue is projected to reach USD 1.380 billion by 2032 at a CAGR of 6.4%. Gallbladder surgery, colorectal resection, bariatric procedures, gastric surgery, and selected liver operations form the main demand base. Competition from bipolar sealers, monopolar instruments, staplers, clips, ligatures, and conventional tools moderates growth.

 

By End User

Hospitals held the largest end-user share at an estimated 68.0% in 2025, equal to USD 2.768 billion. The segment is projected to reach USD 4.650 billion by 2032 at a CAGR of 7.7%. Hospitals perform the widest range of relevant procedures and are the main purchasers of generators, service arrangements, multispecialty platforms, and disposable instruments.

Ambulatory surgical centers accounted for an estimated 22.0% share and USD 895 million in 2025. Revenue is forecast to reach USD 1.800 billion by 2032 at a CAGR of 10.5%, the fastest rate among end users. ASCs benefit from outpatient migration and favor platforms supporting rapid room turnover, predictable supply costs, compact equipment, and standardized procedure packs.

Specialized clinics represented approximately 10.0% of the market and USD 407 million in 2025. The segment is projected to reach USD 700 million by 2032 at a CAGR of 8.1%. Demand is concentrated in bariatric, thyroid, gynecologic, oncology, and selected general surgery facilities, often supported by distributors, hospital affiliations, and group purchasing agreements.

 

By Region

North America led the market with an estimated 38.0% share and USD 1.547 billion in 2025. The region is forecast to reach USD 2.600 billion by 2032 at a CAGR of 7.7%. Its position reflects a large surgical base, established advanced-energy adoption, strong hospital purchasing capacity, major suppliers, and a developed reprocessing market.

Europe accounted for an estimated 27.0% share and USD 1.099 billion in 2025. Revenue is projected to reach USD 1.820 billion by 2032 at a CAGR of 7.5%. Established laparoscopic practices, replacement demand, and product introductions support the market, although procurement, reimbursement, and tender systems differ by country.

Asia-Pacific represented an estimated 25.0% share and USD 1.018 billion in 2025. The region is projected to reach USD 2.030 billion by 2032 at a CAGR of 10.4%, making it the fastest-growing region. Expansion is supported by rising minimally invasive surgical capacity, hospital investment, a large patient base, and greater participation by regional manufacturers.

Latin America accounted for approximately 6.0% of global revenue in 2025, equal to USD 244 million. The market is forecast to reach USD 440 million by 2032 at a CAGR of 8.8%, led by private hospitals, large public surgical centers, and investment in minimally invasive procedures.

The Middle East and Africa represented an estimated 4.0% share and USD 163 million in 2025. Revenue is projected to reach USD 260 million by 2032 at a CAGR of 6.9%. Growth depends on tertiary hospital development, surgical training, procurement budgets, distributor coverage, and access to imported equipment and instruments.

 

Competitive Outlook

Johnson & Johnson MedTech, Medtronic, Olympus, and BOWA are among the most visible established suppliers. J&J competes through the HARMONIC portfolio, Medtronic through cordless Sonicision technology, Olympus through hybrid ultrasonic-bipolar systems, and BOWA through alternative ultrasonic platforms. Asian manufacturers and FDA-cleared reprocessors are widening the competitive field.

Future performance will depend on procedure growth, outpatient migration, disposable pricing, generator standardization, reprocessing adoption, product reliability, and long-term hospital contracts. Bariatric surgery faces procedure-volume pressure, while general, gynecologic, colorectal, thyroid, oncology, and ambulatory surgery provide a broader demand base. Competition is shifting toward total procedure economics, platform compatibility, service coverage, supply reliability, and recurring disposable revenue.
 

Ultrasonic Electrosurgical Devices Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.07 Billion
Revenue Forecast in 2032	USD 7.15 Billion
Overall Growth Rate	CAGR of 8.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Ultrasonic Scalpel Systems, Handpieces, Generators
By Application	Minimally Invasive Surgery, Oncology, Gastrointestinal Surgery
By End User	Hospitals, Ambulatory Surgical Centers, Specialized Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growth in high-volume general, gynecological, colorectal, bariatric, thyroid, and oncological surgeries; wider adoption of minimally invasive and robotic-assisted procedures; increasing demand for hybrid ultrasonic-bipolar energy systems; recurring consumption of single-use surgical instruments; migration of suitable procedures to ambulatory surgical centers; demand for improved vessel sealing, lower thermal spread, and faster operating-room workflows
Customization Option	Available upon request